Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/515—Animal cells
  • A61K2039/5156—Animal cells expressing foreign proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55516—Proteins; Peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/24011—Poxviridae
  • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
  • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
  • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S435/00—Chemistry: molecular biology and microbiology
  • Y10S435/81—Packaged device or kit

Definitions

• the present invention relates to the fields of virology, molecular biology, and
• compositions and methods relates to compositions and methods
• p53 is a tumor suppressor protein that regulates the expression of -certain
• the tumor suppressor gene required for cell cycle arrest or apoptosis.
• encoding p53 is activated by DNA damage, cell stress, or the aberrant expression of
• wild type p53.(wt-p53) serves to
• p53 is also involved in inducing apoptosis in cells with certain types of physiologic damage
• p53 expression in cells can occur at the level of p53 mRNA abundance or at the
• Missense point mutations are the most frequent p53 mutations in cancer.
• mutations may represent true tumor specific antigens, most of these mutations occur
• tumor-expressed p53 is
• lymphocyte level (CTL) (Theobald 1997; Erdile 2000), limits the effectiveness of p53-
• the p53 gene product is overexpressed in a majority of cancers, making it an
• tumor-expressed p53 is likely to be tolerated as a
• the present invention is based on the discovery
• p53 a nucleic acid that encodes p53
• CpG ODN CpG oligodeoxynucleotide
• composition in a first aspect, provides a composition comprising
• telomere p53 a nucleic acid encoding p53.
• tbe p53 a nucleic acid encoding p53
• the composition may also contain a CTLA-4 blocker and/or a CpG ODN.
• the present invention provides a method for treating a
• This method is based on
• the method also calls for administration of a CTLA-4 blocker and/or CpG
• the present invention provides a kit
• This kit contains a recombinant MVA
• containing a nucleic acid that encodes p53 and may also contain a CTLA-4 blocker
• this invention provides
• Figure 1 PCR analysis of the pLW22-hup53 construct. rMVAhup53 injected
• the rMVAhup53 product was shown to have no contaminating
• Figure 2 Expression of mup53 by cells infected with r VAmup53.
• infected BHK cells loaded 0.125 ul, 0.25ul cell lysates respectively), 5) rAdp53, and
• Figure 3 Generation of a p53-specific CTL response by rMVAmup53 in vitro.
• mice treated with rMVAmup53 were harvested at 14 days and restimulated in vitro
• Figure 4 Effect of vaccination with rMVAmup53 on Meth A tumor prevention.
• mice were injected subcutaneously (s.c.) with 5 x 10 5 Meth A cells. On day 5,
• the survival plot shows the proportion of surviving animals in each group as a function of days post tumor
• mice vaccinated with rMVAmup53 The improvement of the mice vaccinated with rMVAmup53 over both
• control groups is statistically significant (P ⁇ 1 ) as determined by the log rank test.
• mice 10 6 Meth A cells. On days 6, 9, and 12 mice were injected i.p. with either anti-CTLA-
• mice were vaccinated with either 5 x
• mice vaccinated with rMVAp53 plus anti-CTLA-4 mAb (n 14) over control animals
• mice were injected s.c. with 2 x 10 6 11A-1 cells
• polyclonal antibody (isotype matched Ab) were injected i.p. on days 4, 7, and 10 at
• mice were vaccinated i.p. with
• polyclonal antibody (isotype matched Ab) were injected i.p. on days 4, 7, and 10 at
• mice were vaccinated i.p. with
• mice were immunized
• CpG ODN CpG was injected i.p. on days 4, 9, and 14. On day 5, the mice were
• rMVApp65 (MVApp65), or PBS.
• CpG ODN CpG ODN
• rMVApp65 (MVApp65), or PBS.
• mice were vaccinated
• rMVAmup53 5 x 10 7 pfu of rMVAmup53 (MVAp53), 5 x 10 7 pfu rMVApp65, or PBS.
• the survival plot shows the proportion of surviving animals in each group as a
• Figure 12 Effect of vaccination with rMVAmup53 plus anti-CTLA-4 mAb and
• the survival plot shows the proportion of surviving animals in each group as a
• Balb/c mice (a) or IFN- ⁇ K0 Balb/c mice (b) were injected
• mice from both mice were s.c. with a rapidly lethal dose of 10 6 Meth A cells. Groups of mice from both
• NK1.1 or control mAb on days -1 , 1 , 3, and 10, and weekly thereafter.
• days 6 On days 6,
• mice were injected i.p. with either anti-CTLA-4 mAb (CTLA4mAb) or
• mice were vaccinated with either 5 x 10 7 pfu rMVAp53
• mice 11A-1 tumors.
• Balb/c mice were injected s.c. with 2 x 10 6 11A-1 -cells. 15 nmoles
• mice were vaccinated
• p 0.007, comparing anti-NK1.1 to anti-CD4 and control mAb.
• Figure 15 Cellular requirements for anti-CTLA-4 mAb immunomodulator
• CTLA-4 mAb was injected i.p. on days 4, 7, and 10 at 100, 50, and 50 ⁇ g/dose,
• mice were vaccinated i.p. with 5 x 10 7 pfu rMVAmup53.
• the mice were depleted of CD8 ⁇ CD4 + , or NK cells by i.p. injection with the relevant
• mice were injected s.c. with 1 x 10 6 MC-38 cells. Mice were treated with
• CTLA4 mAb anti-CTLA-4 mAb
• mice were vaccinated i.p. with 5 x 10 7 pfu of rMVAmup53. Tumors were measured
• mice were treated with anti-CTLA-4 mAb ⁇ CTLA4 mAb) on days 4, 7, and 10 at 100,
• mice were vaccinated i.p. with 5 x 10 7 pfu of rMVAmup53.
• Lane 1 BHK cells injected with control MVA; Lane 2: BHK cells
• Lane 3 BHK cells infected with rMVAhup53
• mice received an rMVAhup53 or PBS booster injection, along with 15
• mice nmole of CpG ODN and 50 ⁇ g of anti-CTLA-4 mAb. rMVAhup53 vaccinated mice
• the present invention is based on the discovery that self-tolerance to a
• the invention provides novel cell-free compositions and methods for the
• rMVAmup53 or rMVAhup53 stimulates a vigorous p53-specific CTL response.
• CTLA-4 blocker consisting of a CTLA-4 blocker and/or CpG ODN.
• MVA virus (GenBank Accession Number U94848) is a variant of the Ankara
• MVA immunosuppressive effects of the cancer itself.
• poxviruses such as the WR strain could not be safely administered to
• primers will generally include at least a 10 base pair sequence
• MVA recombination plasmid such as pMC03, pLW22, pLW51 , pUCII LZ or other MVA transfer vectors well known in the art.
• the recombination plasmid contains
• rMVAhup53 was analyzed to determine the fidelity and extent of its expression from
• Meth A cells which overexpress mutated p53, were used as a
• recombinant viruses may also avoid the need for a complex and expensive
• rMVAmup53 could break p53 tolerance, resulting in the generation of p53-specific
• Splenocytes were harvested from mice following a single intraperitoneal (i.p.)
• the splenocytes recognized and lysed wt p53 over-expressing targets.
• mice vaccinated with rMVApp65 which stimulates
• mice vaccinated with rMVAmup53 Restimulated splenocytes from mice vaccinated with rMVAmup53
• rMVAmup53 was shown to inhibit the outgrowth of murine sarcoma Meth A, an
• mice A majority of the vaccinated mice failed to develop tumors entirely, and
• CTLA-4 blocker or CpG ODN immunomodulator Immunization with vaccinia viral
• the DC present antigen to naive CD8 + T cells
• CTLA-4 a phenomenon referred to as "CTLA-4 blockade.”
• CTLA-4 is a cell surface receptor found on T cells. Activation of CTLA-4 leads to inhibition of
• CTLA-4 plays a significant role in regulating peripheral T-cell tolerance by interfering with T-cell activation through both passive and active
• cancer vaccines expressing tumor associated autoantigens can, in some cases,
• CTLA-4 blockade lowers the T-cell activation threshold and removes the
• CTLA-4 blockade also inhibits Treg cell activity in
• CTLA-4 blockade results in rejection of established poorly immunogenic melanoma
• CTLA-4 blocking agents are molecules that are structurally identical to tumor associated antigens.
• a CTLA-4 blocking agent can be a monoclonal or polyclonal
• antibody a fragment of an antibody, a peptide, a small organic molecule, a
• peptidomimetic a nucleic acid such as interfering RNA (iRNA) or antisense
• iRNA interfering RNA
• Anti-CTLA-4 antibodies may be generated by
• Monoclonal antibodies to CTLA-4 can be produced by
• CTLA-4 mAb may include rat, mouse, hamster, sheep, or human cells.
• mAbs may be purified from hybridoma cell supematants or from ascites fluid.
• CTLA-4 antibodies may be human antibodies generated using transgenic animals
• Anti-CTLA-4 antibodies also encompasses chimeric and
• antibodies to CTLA-4 may be generated by recombinant methods to contain only the
• human region may be substituted with residues from the human antibody framework.
• antibodies to CTLA-4 can be the product of an animal having transgenic buman
• immunoglobulin constant region genes are also be engineered by
• guanine motifs are potent immunostimulatory agents that can enhance vaccine
• TLR9 Toll-like Receptor-9
• CpG ODN has been shown to be an effective adjuvant for a variety
• CpG ODN can enhance the effect of peptide (Davila 2000; Stern 2002), protein (Kim
• antitumor effect was primarily CD8 ⁇ and to a lesser extent CD4 ⁇ dependent.
• 11 A-1 is a rapidly growing malignant cell
• MC-38 is a colon carcinoma cell line. Mice injected
• CTLA-4 mAb was replaced with CpG ODN.
• rMVAhup53 was administered to hupki mice injected with 4T1 ⁇ H-2 d ) cells
• 4T1 (H-2 d ) is a murine breast carcinoma
• mice were vaccinated with rMVAhup53 6 days after injection with 4T1 cells,
• rMVAhup53 cell-free vaccine at eliciting an immune response targeting p53 in a
• composition comprising a recombinant MVA virus engineered to express
• the present invention further provides an immunotherapeutic
• rMVAp53 Introduction of rMVAp53 into a subject can be performed by any procedure
• rMVAp53 can be administered by intravascular
• rMVAp53 can be prepared as a formulation at an effective dose in pharmaceutically acceptable media, such as normal saline,
• Therapeutic preparations may include
• physiologically tolerable liquids gel or solid carriers, diluents, adjuvants and
• Additives may include bactericidal agents, additives that maintain
• isotonicity e.g., NaCI, mannitol
• additives that maintain chemical stability e.g., sodium chloride, sodium sulfate, sodium EDTA, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite
• rMVAp53 may be formulated as a solution, suspension, emulsion or lyophilized
• Liposomes or non-aqueous vehicles such as fixed oils, may also be used.
• formulation may be sterilized by techniques known in the art.
• the rMVAp53 formulation can be further enhanced with a costimulator, such as
• cytokine as a cytokine, tumor antigen, an antigen derived from a pathogen, or any
• the costimulator can be any agent that directly or indirectly
• MVA can be any suitable for its ability to modulate APC or T-cell function.
• MVA can be any suitable for its ability to modulate APC or T-cell function.
• MVA can be any suitable for its ability to modulate APC or T-cell function.
• MVA can be any suitable for its ability to modulate APC or T-cell function.
• MVA can be any suitable for its ability to modulate APC or T-cell function.
• MVA can be any suitable for its ability to modulate APC or T-cell function.
• GM-CSF GM-CSF
• IL-12 IL-12
• other stimulatory cytokines IL-12
• costimulator and the combination of rMVAp53 and costimulator (here: MVA
• expressing the stimulatory cytokine can be introduced into the subject.
• treatment may be performed in combination with administration of cytokines that
• GM-CSF macrophage colony stimulating factor
• M-CSF macrophage colony stimulating factor
• G-CSF granulocyte colony stimulating factor
• IL-3 interieukin 3
• IL- 12 interieukin 12
• costimulators include cytokine- transduced tumor cells, such as tumor cells transduced with GM-CSF, as well as
• tumor cells that have been irradiated and/or treated with a chemotherapeutic agent
• Chemotherapeutic or radiotherapeutic agents are further provided.
• rMVAp53 can be administered in conjunction with
• T cells to antigenic stimulation.
• the determination of the T cell response will vary
• cytokines including, IL-2, IFN ⁇ , TNF ⁇ , etc.
• the dosage of the therapeutic formulation will vary
• the dosage administered will vary depending on
• the dose may be administered as infrequently as weekly or biweekly, or
• a daily dosage of active ingredient can be about 10 6 -10 11 lU
• administration generally contain from about 10 6 to 10 12 IU of active ingredient per unit.
• the active ingredient may vary from 0.5 to 95% by weight based on the total
• the number of T cells may be monitored in a patient by
• rMVAp53 is administered
• an immunomodulator specifically a CTLA-4 blocking agent or a
• anti-CTLA-4 mAb is unexpectedly potent in producing regression of advanced tumors
• immunomodulators are administered in conjunction with rMVAp53.
• the immunomodulators are administered in conjunction with rMVAp53.
• anti-CTLA-4 mAb CpG ODN immunomodulators are nontoxic to the subject, and
• mAb, and CpG ODN can be administered by intravascular, subcutaneous, peritoneal,
• rMVAp53, anti-CTLA-4 mAb, and CpG ODN can be administered together, separately, or sequentially, in any order, by the same route of administration or by
• rMVAp53 plus anti-CTLA-4 mAb and/or CpG ODN can be prepared
• preparations may include physiologically tolerable liquids, gel or solid carriers,
• Additives may include bactericidal agents,
• additives that maintain isotonicity e.g. NaCI, mannitol
• chemical stability e.g.
• CpG ODN may be administered as a cocktail or as single agents.
• anti-CTLA-4 mAb and CpG ODN may be formulated as a
• the formulation may be sterilized by
• the rMVAp53 plus anti-CTLA-4 mAb and/or CpG ODN combination can be
• a costimulator such as a cytokine, tumor antigen, or antigen
• a costimulator can be any agent that directly or indirectly
• MVA can be any suitable anti-CTLA-4 mAb and/or CpG ODN.
• MVA can be any suitable anti-CTLA-4 mAb and/or CpG ODN.
• MVA can be any suitable anti-CTLA-4 mAb and/or CpG ODN.
• MVA can be any suitable anti-CTLA-4 mAb and/or CpG ODN.
• MVA can be any suitable anti-CTLA-4 mAb and/or CpG ODN.
• costimulator and the combination of rMVAp53 and costimulator (here: MVA
• ODN and costimulator can be introduced into the subject.
• the treatment may be performed in combination with administration of cytokines that stimulate antigen
• presenting cells such as granulocyte-macrophage colony stimulating factor ⁇ GM-
• M-CSF macrophage colony stimulating factor
• G-CSF G-CSF
• interieukin 3 IL-3
• interieukin 12 IL-12
• costimulators include cytokine-transduced tumor cells such as tumor
• radiotherapeutic agents are further examples of costimulators.
• rMVAp53 rMVAp53
• the dosage of the therapeutic formulation will vary widely, depending upon
• the dosage administered will vary
• the dose may be administered as infrequently as
• a daily dosage of active ingredient can be about 0.1 to
• Dosage forms suitable for internal administration generally contain from about 0.1 mg to 500 mgs of active ingredient per unit.
• active ingredient may vary from 0.5 to 95% by weight based on the total weight of
• composition In some cases it may be desirable to limit the period of treatment
• T cells may be monitored in a patient by methods known
• T cell response The determination of the T cell response will vary with the
• T cell activity Useful measures of T cell activity are proliferation,
• cytokines including. IL-2, IFN ⁇ , TNF ⁇ , etc; T cell expression of
• markers such as CD25 and CD69; and other measures of T cell activity as known in
• the present invention further provides a kit that will allow the artisan to
• kits comprises rMVAp53, a CTLA-4
• kit may further comprise one or more pharmaceutically acceptable carriers.
• compositions of the kit are administered in pharmaceutically
• compositions of the invention refer to providing the compositions of the invention as a medicament to an individual
• This medicament which contains compositions of the present invention as the principal
• kits of the invention provide compositions for parenteral
• compositions dissolved or suspended
• compositions may be in an acceptable carrier, preferably an aqueous carrier.
• an acceptable carrier preferably an aqueous carrier.
• tonicity adjusting agents including -sodium acetate
• Such preparations may routinely contain pharmaceutically acceptable
• supplementary immune potentiating agents such as adjuvants and cytokines and
• An effective amount is that amount of a
• the desired response is inhibiting the initiation or progression of the cancer, or producing regression of the cancer.
• individual patient parameters including age, physical condition, size, weight, and the
• nucleic acid due to the degeneracy of the genetic code, nucleic acid sequence, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino
• mice on the Balb/c background were obtained from The Jackson
• mice were a kind gift from Dr. Shizuo Akira
• Meth A was passaged as an ascitic
• Anti-CD8 H35
• Anti-CTLA-4 mAb
• IgG antibodies were purified by absorbance over protein
• rMVA expressing murine o53 (rMVAmup53):
• Wild type MVA was obtained from Dr. Bernard Moss and Dr. Linda
• rMVA recombinant MVA
• the wtMVA stock is a specific pathogen free chicken embryo fibroblasts (SPF/CEF).
• SPF/CEF specific pathogen free chicken embryo fibroblasts
• Murine p53 (mup53) is analogous to human p53, with 80% sequence
• murine and human p53 makes the murine system an excellent preclinical model for
• expressing murine p53 was generated by homologous recombination of wtMVA and
• the murine p53 PCR product was
• deletion III of the MVA genome and also contains the gus (E. coli B-glucuronidase)
• the rMVAmup53 was expanded on BHK-21 monolayers.
• rMVAmup53 titer was determined by immunostaining infected cultures using the
• Vectastain Elite ABC Kit Vector Laboratories, Burlingame, CA.
• rMVA expressing human p53 rMVAhup53V.
• rMVAhup53 Two different constructs of rMVA expressing human p53 (rMVAhup53) were
• pLW51 was used as the insertion plasmid for generating the first rMVAhup53
• pLW51 has four important features. First, it contains MVA flanking
• DR1 contains two direct repeats composed of MVA sequence (designated as DR1 and DR2
• MCS multiple cloning sites
• the first MCS is behind an
• foci are pulled from the first rounds of screening to ensure that a correct recombinant
• hup53 is plated at low dilution in 24 well plates. Wells that do not have a color
• hup53 gene product This is accomplished by antibody staining using conditions
• pLW22 was used as the insertion plasmid for generating the second
• pLW22 has MVA flanking regions that allow it to insert into MVA via homologous recombination. It also has a color screening marker gene, ⁇ -
• Amplified wt hup53 DNA was inserted into the pLW22 vector between restriction
• pLW22-hup53 is shown in SEQ ID NO: 5.
• rMVA expressing hup53 was screened for ⁇ -gal
• the rMVA titer was determined by immunostaining
• a second set of PCR primers are designed to amplify a
• PCR samples are run on a 1 % agarose gel and analyzed
• rMVA expressing pp65 (rMVApp65), a CMV tegument protein, was
• CMV was cotransformed into BJ5183 cells with the pAd Easy-1 plasmid to generate
• the p53 recombinant adenoviral construct was cleaved with Pac I and transfected
• rAd-mup53 was harvested 5 days after transfection and p53
• the protein expression was confirmed by western blot.
• the adenovirus was expanded
• the purified virus was
• Synthetic ODN 1826 with CpG motifs (SEQ ID NO: 6) and non-CpG ODN
• Example 1 Expression of murine p53 protein by rMVAmup53:
• Lysates were prepared from BHK or HEK 293 cells infected with rMVAmup53
• volume on the rMVAmup53 lane is between 80-160 fold less than what was applied
• Meth A is a Balb/c derived, tumorigenic 3-
• Example 2 In vitro generation of a p53-specific CTL response by rMVAmup53:
• mice were vaccinated i.p.
• rMVAmup53 vaccination can also stimulate CTL recognition of a cell line
• rMVAmup53 recognized mutant p53 over-expressing Meth A cells, but splenocytes
• mice Six-week-old female Balb/c mice were injected by subcutaneous (s.c.) route
• mice were vaccinated with 5x10 7 pfu of rMVAmup53 by
• the s.c. tumors were measured twice weekly in three
• CTLA-4 specific to CTLA-4 was added to rMVAmup53 vaccination to determine whether it
• mice were injected i.p. with 5x10 7 pfu of rMVAmup53. Controls were the same as
• Anti-CTLA-4 mAb antibody or control hamster Ab were injected i.p. on days
• mice 6, 9, and 12 at 100, 50 and 50 ⁇ g dose, respectively. 11 of the 14 mice immunized
• mice treated with rMVApp65 and control antibody died rapidly of progressive tumor
• mice also rejected a re-challenge with 10 6 Meth A tumor cells at 60 days, and remained tumor free for the duration of a 30
• mice Six-week-old Balb/c mice were injected s.c. in the left flank with 2 x 10 6 11A-1
• 11 A-1 is a rapidly growing malignant cell line that is poorly immunogenic.
• mice were vaccinated i.p. with either 5 x 10 7 pfu of
• mice Six-week-old C57BL/6 mice, TLR9 " ' " , or IL-6 " ' “ mice were injected s.c. in the left
• mice were vaccinated i.p. with either 5 x 10 7 pfu of rMVAmup53, 5 x 10 7
• ODN control were injected i.p. on days 4, 9, and 14. On day 5, the mice were
• the s.c. tumors were measured twice weekly in three dimensions with calipers.
• mice old Balb/c mice were injected s.c. in the left flank with 2 x 10 6 11A-1 cells and
• control hamster antibody was injected i.p. on days 14, 17, and 20, at 100, 50, and 50
• mice were vaccinated i.p. with either 5 x 10 7 pfu of rMVAmup53,
• mice bearing MC-38 tumors were treated with rMVAmup53 plus a
• Example 4 Cellular reguirements for anti-CTLA-4 mAb and CpG ODN
• mice were depleted of CD4 + , CD8 ⁇ or NK
• CD4 ⁇ CD8 + or NK1.1 cell specific mAbs, or a control mAb. Injections were given on
• CD4 + , CD8 + , or NK 1.1 cells based on flow cytometry of peripheral blood from
• mice in Balb/c mice. Mice depleted of CD8 + T cells or CD4 + and CD8 + T cells
• Results were the same when the depleting mAbs were administered after
• rMVAmup53 vaccination were evaluated using Balb/c mice with four-day established
• CD4 + and NK between anti-CTLA-4 mAb and CpG ODN is striking, because both
• mice vaccinated with rMVApp65 and anti-CTLA-4 mAb developed lethal tumors

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Biochemistry (AREA)
• Wood Science & Technology (AREA)
• Molecular Biology (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Biophysics (AREA)
• Biomedical Technology (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Plant Pathology (AREA)
• Virology (AREA)
• Toxicology (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (4)

Applications Claiming Priority (4)

Publications (2)

Family

ID=32685446

Family Applications (1)

Country Status (6)

Cited By (25)

Families Citing this family (8)

Family Cites Families (4)

• 2003
  • 2003-12-22 CA CA002511625A patent/CA2511625A1/en not_active Abandoned
  • 2003-12-22 WO PCT/US2003/041053 patent/WO2004058801A2/en not_active Ceased
  • 2003-12-22 EP EP03814346A patent/EP1575611A4/en not_active Withdrawn
  • 2003-12-22 AU AU2003297499A patent/AU2003297499A1/en not_active Abandoned
  • 2003-12-22 JP JP2005510053A patent/JP2006512097A/ja not_active Withdrawn
  • 2003-12-23 US US10/746,558 patent/US7256037B2/en not_active Expired - Lifetime
• 2007
  • 2007-05-21 US US11/805,180 patent/US7563448B2/en not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events